Literature DB >> 34548638

Endolysosomal ion channel MCOLN2 (Mucolipin-2) promotes prostate cancer progression via IL-1β/NF-κB pathway.

Hongyan Yu1,2,3, Mingxu Xie1,2, Zhaoyue Meng1,2, Chun-Yin Lo1,2, Franky Leung Chan1, Liwen Jiang4, Xiangqi Meng5,6, Xiaoqiang Yao7,8,9.   

Abstract

BACKGROUND: Prostate cancer (Pca) is the most common cancer type among males worldwide. Dysregulation of Ca2+ signaling plays important roles during Pca progression. However, there is lack of information about the role of endolysosomal Ca2+ -permeable channels in Pca progression.
METHODS: The expression pattern of MCOLN2 was studied by immunohistochemistry and western blot. Cell viability assay, transwell assay and in vivo tumorigenesis were performed to evaluate the functional role of MCOLN2. Downstream targets of MCOLN2 were investigated by cytokine array, enzyme-linked immunosorbent assay, Ca2+ release experiments and luciferase reporter assays.
RESULTS: We report that MCOLN2 expression is significantly elevated in Pca tissues, and associated with poor prognosis. Overexpression of MCOLN2 promoted Pca cells proliferation, migration and invasion. Importantly, knockdown of MCOLN2 inhibited Pca xenograft tumor growth and bone lesion development in vivo. In addition, MCOLN2 promoted the production and release of IL-1β. Moreover, luciferase reporter assay and western blot revealed that MCOLN2 promoted Pca development by regulating the IL-1β/NF-κB pathway.
CONCLUSION: In summary, MCOLN2 is crucially involved in Pca progression. Mechanistically, MCOLN2 regulates Pca progression via IL-1β/NF-κB pathway. Our study highlights an intriguing possibility of targeting MCOLN2 as potential therapeutic strategy in Pca treatment.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34548638      PMCID: PMC8575885          DOI: 10.1038/s41416-021-01537-0

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  38 in total

1.  Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Horwich; C Parker; C Bangma; V Kataja
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Integrative genomic profiling of human prostate cancer.

Authors:  Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald
Journal:  Cancer Cell       Date:  2010-06-24       Impact factor: 31.743

3.  Two-Pore Channel Function Is Crucial for the Migration of Invasive Cancer Cells.

Authors:  Ong Nam Phuong Nguyen; Christian Grimm; Lina S Schneider; Yu-Kai Chao; Carina Atzberger; Karin Bartel; Anna Watermann; Melanie Ulrich; Doris Mayr; Christian Wahl-Schott; Martin Biel; Angelika M Vollmar
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

4.  Essential role for Ca2+ in regulation of IL-1beta secretion by P2X7 nucleotide receptor in monocytes, macrophages, and HEK-293 cells.

Authors:  Lalitha Gudipaty; Jonathan Munetz; Philip A Verhoef; George R Dubyak
Journal:  Am J Physiol Cell Physiol       Date:  2003-03-26       Impact factor: 4.249

Review 5.  Targeting bone metastases in prostate cancer: improving clinical outcome.

Authors:  Jean-Jacques Body; Sandra Casimiro; Luís Costa
Journal:  Nat Rev Urol       Date:  2015-05-05       Impact factor: 14.432

Review 6.  Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation.

Authors:  Charles A Dinarello
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

7.  Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.

Authors:  Qingxin Liu; Mike R Russell; Kristina Shahriari; Danielle L Jernigan; Mercedes I Lioni; Fernando U Garcia; Alessandro Fatatis
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

8.  NF-κB and Nrf2 signaling pathways contribute to wogonin-mediated inhibition of inflammation-associated colorectal carcinogenesis.

Authors:  J Yao; L Zhao; Q Zhao; Y Zhao; Y Sun; Y Zhang; H Miao; Q-D You; R Hu; Q-L Guo
Journal:  Cell Death Dis       Date:  2014-06-05       Impact factor: 8.469

9.  Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.

Authors:  Liwei Lang; Chloe Shay; Xiangdong Zhao; Yong Teng
Journal:  J Exp Clin Cancer Res       Date:  2017-08-23

Review 10.  Endolysosomal Ca2+ Signaling in Cancer: The Role of TPC2, From Tumorigenesis to Metastasis.

Authors:  Abeer F Alharbi; John Parrington
Journal:  Front Cell Dev Biol       Date:  2019-12-04
View more
  4 in total

1.  Cytohesin-2/ARNO: A Novel Bridge Between Cell Migration and Immunoregulation in Synovial Fibroblasts.

Authors:  Yilin Wang; Çağlar Çil; Margaret M Harnett; Miguel A Pineda
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

Review 2.  Regulation of Aging and Longevity by Ion Channels and Transporters.

Authors:  Kartik Venkatachalam
Journal:  Cells       Date:  2022-03-31       Impact factor: 6.600

3.  Coexpression of TRPML1 and TRPML2 Mucolipin Channels Affects the Survival of Glioblastoma Patients.

Authors:  Giorgio Santoni; Federica Maggi; Consuelo Amantini; Antonietta Arcella; Oliviero Marinelli; Massimo Nabissi; Matteo Santoni; Maria Beatrice Morelli
Journal:  Int J Mol Sci       Date:  2022-07-13       Impact factor: 6.208

4.  Functional In Vitro Assessment of VEGFA/NOTCH2 Signaling Pathway and pRB Proteasomal Degradation and the Clinical Relevance of Mucolipin TRPML2 Overexpression in Glioblastoma Patients.

Authors:  Giorgio Santoni; Consuelo Amantini; Massimo Nabissi; Antonietta Arcella; Federica Maggi; Matteo Santoni; Maria Beatrice Morelli
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.